Wang Nelson, Tsai Yi-Chin, Niles Natasha, Tchantchaleishvili Vakhtang, Di Eusanio Marco, Yan Tristan D, Phan Kevin
Department of Medicine, University of Sydney, Sydney, Australia.
The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia.
J Thorac Dis. 2016 Nov;8(11):3283-3293. doi: 10.21037/jtd.2016.11.100.
With improving technologies and an increasingly elderly populations, there have been an increasing number of therapeutic options available for patients requiring aortic valve replacement. Recent evidence suggests that transcatheter aortic valve implantation (TAVI) is one suitable option for high risk inoperable patients, as well as high risk operable patients. Sutureless valve technology has also been developed concurrently, with facilitates surgical aortic valve replacement (SUAVR) by allow resection and replacement of the native aortic valve with minimal sutures and prosthesis anchoring required. For patients amenable for both TAVI and SUAVR, the evidence is unclear with regards to the benefits and risks of either approach. The objectives are to compare the perioperative outcomes and intermediate-term survival rates of TAVI and SUAVR in matched or propensity score matched studies.
A systematic literature search was performed to include all matched or propensity score matched studies comparing SUAVR versus TAVI for severe aortic stenosis. A meta-analysis with odds ratios (OR) and mean differences were performed to compare key outcomes including paravalvular regurgitation and short and intermediate term mortality.
Six studies met our inclusion criteria giving a total of 741 patients in both the SUAVR and TAVI arm of the study. Compared to TAVI, SUAVR had a lower incidence of paravalvular leak (OR =0.06; 95% CI: 0.03-0.12, P<0.01). There was no difference in perioperative mortality, however SUAVR patients had significantly better survival rates at 1 (OR =2.40; 95% CI: 1.40-4.11, P<0.01) and 2 years (OR =4.62; 95% CI: 2.62-8.12, P<0.01).
The present study supports the use of minimally invasive SUAVR as an alternative to TAVI in high risk patients requiring aortic replacement. The presented results require further validation in prospective, randomized controlled studies.
随着技术的进步和人口老龄化加剧,对于需要进行主动脉瓣置换的患者,治疗选择越来越多。近期证据表明,经导管主动脉瓣植入术(TAVI)对于高风险无法手术的患者以及高风险可手术的患者而言是一种合适的选择。无缝合瓣膜技术也在同步发展,通过允许以最少的缝线和假体固定来切除和置换天然主动脉瓣,从而促进了外科主动脉瓣置换术(SUAVR)。对于适合TAVI和SUAVR两种手术的患者,关于这两种方法的益处和风险的证据尚不清楚。目的是在匹配或倾向评分匹配研究中比较TAVI和SUAVR的围手术期结果和中期生存率。
进行了一项系统的文献检索,纳入所有比较SUAVR与TAVI治疗重度主动脉瓣狭窄的匹配或倾向评分匹配研究。采用比值比(OR)和均值差进行荟萃分析,以比较包括瓣周反流和短期及中期死亡率在内的关键结果。
六项研究符合我们的纳入标准,研究的SUAVR组和TAVI组共有741例患者。与TAVI相比,SUAVR的瓣周漏发生率较低(OR = 0.06;95%CI:0.03 - 0.12,P < 0.01)。围手术期死亡率无差异,然而SUAVR患者在1年(OR = 2.40;95%CI:1.40 - 4.11,P < 0.01)和2年(OR = 4.62;95%CI:2.62 - 8.12,P < 0.01)时的生存率显著更高。
本研究支持在需要进行主动脉置换的高风险患者中,使用微创SUAVR替代TAVI。所呈现的结果需要在前瞻性随机对照研究中进一步验证。